Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Natural Products

Croda partnership boosts Botanical Solution’s series A haul

by Craig Bettenhausen
August 31, 2023 | A version of this story appeared in Volume 101, Issue 29

 

A team of people in clean-room suits have a discussion in front of several racks of milk-jug-sized bioreactors.
Credit: Botanical Solution
Botanical Solution cultures plant cells to produce medical-grade specialty chemicals, such as the vaccine adjuvant QS-21.

The industrial biotechnology start-up Botanical Solution has added $7 million to the series A funding round it initially closed in January 2022, for a total of $13 million. The add-on fundraising was led by Otter Capital and was based on a partnership the start-up struck in May with Croda to develop a cell-culture based route to QS-21, an oligosaccharide used in vaccines, including for COVID-19. QS-21 is otherwise extracted from a rare tree species found mostly in Chile.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.